<DOC>
	<DOCNO>NCT02845596</DOCNO>
	<brief_summary>The purpose study determine feasibility compare outcome patient treat de novo immunosuppressive therapy ( IST ) versus match unrelated donor ( MUD ) hematopoietic stem cell transplant ( HSCT ) pediatric acquire severe aplastic anemia .</brief_summary>
	<brief_title>Unrelated Donor Transplant Versus Immune Therapy Pediatric Severe Aplastic Anemia</brief_title>
	<detailed_description>A major challenge treat pediatric Severe Aplastic Anemia ( SAA ) determination best primary therapy patient lack fully match relate donor HSCT . Good survival outcome see IST , initial late failure , CSA dependence , persistent cytopenia secondary Myelodysplastic Syndrome ( MDS ) / Acute Myeloid Leukemia ( AML ) portion patient leave considerable room improvement . MUD HSCT survival SAA markedly improve , direct comparison approach IST necessary determine whether approach feasible lead well Event Free Survival . This trial address feasibility randomization , test whether patient evaluate timely fashion safely begin therapy MUD HSCT IST , give preliminary assessment safety up-front MUD HSCT . If successful , trial lead future prospective trial compare directly IST MUD HSCT disease .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>1 . Confirmed diagnosis idiopathic SAA , define : Bone marrow cellularity &lt; 25 % , &lt; 30 % hematopoietic cell central pathology review consistent SAA ( see laboratory manual procedure ) . Two three follow ( peripheral blood ) : neutrophil &lt; 0.5 x109/L , platelet &lt; 20 x109/L , reticulocyte count &lt; 60 x109/L hemoglobin &lt; 8g/dL . 2 . Age ≤25 year old . 3 . No suitable fully match related donor available ( minimum 6/6 match Human Leukocyte antigen ( HLA ) A B intermediate high resolution DRB1 high resolution use DNA base typing ) . 4 . Unrelated donor donor note National Marrow Donor Program ( NMDP ) search well match ( 9/10 10/10 HLAA , B , C , DRB1 , DQB1 use high resolution ) . See section 2.5.1 detail central confirmation availability donor require . 5 . Signed informed consent randomize trial patient and/or legal guardian . 6 . Adequate organ function define judgment investigator , irreversible organ damage would preclude patient meeting organ function inclusion criterion HSCT list section 2.3.4 intended time HSCT ( 68 week randomization ) preclude patient receive horse ATG . 1 . Inherited bone marrow failure syndrome ( IBMFS ) . The diagnosis Fanconi anemia must exclude diepoxybutane ( DEB ) equivalent test peripheral blood marrow . Dyskeratosis congenita must exclude test telomere length , Shwachman Diamond syndrome must exclude test serum trypsinogen patient age &lt; 3 isoamylase child ≥3 ( see section 4.2.3.1 detail require evaluation exclude IBMFS ) . 2 . Clonal cytogenetic abnormality fluorescence In Situ Hybridization ( FISH ) pattern consistent premyelodysplastic syndrome ( preMDS ) MDS marrow examination ( see section 4.2.3.1 detail require MDS FISH panel ) . 3 . Known severe allergy horse ATG . 4 . Prior allogeneic stem cell transplant . 5 . Prior solid organ transplant . 6 . Seropositive human immunodeficiency virus ( HIV ) . 7 . Active Hepatitis B C determine serology and/or NAT . 8 . Female patient pregnant breastfeeding . 9 . Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>